MNKD Q4 2023 Earnings — MannKind Corporation Revenue & Financial Results | Market Cap Arena

MNKDMannKind Corporation

$813M

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$58M+62.2% YoY

Gross Profit

$40M69.1% margin

Operating Income

$8M13.4% margin

Net Income

$1M2.4% margin

EPS (Diluted)

$0.00

QoQ Revenue Growth

+14.1%

Cash Flow

Operating Cash Flow

$22M

Free Cash Flow

$16M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$475M

Total Liabilities

$721M

Stockholders' Equity

-$246M

Cash & Equivalents

$238M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$58M	$36M	+62.2%
Gross Profit	$40M	$20M	+102.7%
Operating Income	$8M	-$13M	+161.4%
Net Income	$1M	-$18M	+107.8%

Revenue Segments

License and Service

$23M100%